Rimabotulinumtoxinb - Biologic Drug Details

Summary for rimabotulinumtoxinb

Tradenames:	1
High Confidence Patents:	4
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for rimabotulinumtoxinb

Mechanism of Action	Acetylcholine Release Inhibitors
Established Pharmacologic Class	Acetylcholine Release Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for rimabotulinumtoxinb Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for rimabotulinumtoxinb Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	5,512,547	2014-10-13	DrugPatentWatch analysis and company disclosures
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	6,290,961	2020-01-24	DrugPatentWatch analysis and company disclosures
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	6,632,433	2021-06-18	DrugPatentWatch analysis and company disclosures
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	6,872,397	2021-03-15	DrugPatentWatch analysis and company disclosures
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	6,887,476	2021-06-18	DrugPatentWatch analysis and company disclosures
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	7,211,261	2019-09-09	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for rimabotulinumtoxinb Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	10,064,921	2037-03-02	Patent claims search
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	10,076,557	2034-09-23	Patent claims search
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	10,231,665	2034-09-18	Patent claims search
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	10,478,478	2038-03-30	Patent claims search
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	10,656,152	2037-11-08	Patent claims search
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	10,722,552	2039-10-18	Patent claims search

International Patents for rimabotulinumtoxinb

Country	Patent Number	Estimated Expiration
Germany	69434008
Japan	2005281317
Hong Kong	1071071
Canada	2310845
Germany	69434610
Japan	H09507234

Supplementary Protection Certificates for rimabotulinumtoxinb

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
132010901814274	Italy		AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/166/001-003, 20010122
10C0007	France		PRODUCT NAME: TOXINE BOTULIQUE DE TYPE B; REGISTRATION NO/DATE: EU/1/00/166/001 20010122
122008000043	Germany		PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531
132008901655481	Italy		PRODUCT NAME: NEUROTOSSINA DI CLOSTRIDIUM BOTULINUM DI TIPO A (150 KD) PRIVA DI PROTEINE COMPLESSATE(XEOMIN); AUTHORISATION NUMBER(S) AND DATE(S): 838, 20080409;57093.00.00, 20050531
122009000066	Germany		PRODUCT NAME: BOTULINUMTOXIN TYP B; REGISTRATION NO/DATE: EU/1/00/166/001-003 20010122
SPC/GB10/013	United Kingdom		PRODUCT NAME: BOTULINUM TOXIN TYPE B; REGISTERED: UK EU/1/00/166/001-003 20010125

Market Dynamics and Financial Trajectory for RimabotulinumtoxinB

Last updated: February 20, 2026

What is RimabotulinumtoxinB?

RimabotulinumtoxinB (Myobloc) is a botulinum toxin type B developed by Elan Pharmaceuticals, now marketed by Ipsen. It is approved primarily for cervical dystonia, sialorrhea, and certain other movement disorders. Its distinct mechanism involves inhibiting acetylcholine release at neuromuscular junctions, leading to muscle paralysis.

Market Size and Growth Drivers

Global Market Valuation

The botulinum toxin market, including type A and B formulations, is valued at approximately $4.7 billion in 2022. RimabotulinumtoxinB accounts for roughly 8% of this market, with an estimated size of $370 million.

Compound Annual Growth Rate (CAGR)

Between 2020 and 2027, the overall botulinum toxin market is expected to grow at a CAGR of 7%. RimabotulinumtoxinB is projected to expand at 6-8%. This projection considers clinical demand in movement disorders, an increasing prevalence of cervical dystonia, and expansion into new indications.

Key Growth Catalysts

• Expansion into new indications: Widening from movement disorders to severe hyperhidrosis and off-label uses.
• Advances in delivery: Development of neuromodulation techniques and formulation optimization.
• Increasing awareness and diagnosis: Improved identification of dystonia and related conditions.
• Competitive positioning: As a toxin B, RimabotulinumtoxinB is often used when toxin A formulations are contraindicated or less effective.

Competitive Landscape

Major Players

• Dysport/Adravant (botulinum toxin A): Market leader with over 50% share.
• Xeomin (botulinum toxin A): Focused on autoimmune and neuromuscular conditions.
• Botulinum toxin B formulations: RimabotulinumtoxinB is the primary product with approved indications; however, competitors such as NeuroBloc (China) and Neurotoxina (Russia) exist in local markets.

Market Share Distribution

Product Name	Market Share	Indications	Formulation Type
Dysport/Adravant	50%	Cervical dystonia, cosmetic uses	Type A
Xeomin	20%	Dopaminergic dystonia, spasticity	Type A
RimabotulinumtoxinB	8%	Cervical dystonia, sialorrhea	Type B

Patent and Regulatory Status

• Patent Expiry: The core patent for RimabotulinumtoxinB expired in 2013, opening avenues for generic production.
• FDA Approval: Approved in 2000 for cervical dystonia; also approved for sialorrhea.
• EMA Approval: Same indications, with some additional off-label uses documented.

Revenue Trends and Financial Trajectory

Historical Revenue Data

Year	Revenue (USD millions)	Notes
2015	150	Steady growth, limited indications
2018	200	Expanded indications, increasing demand
2020	270	Market expansion, new formulations
2022	370	Peak market size, impact of competitive pressure

Future Revenue Projections

• 2023–2027 CAGR: Estimated at 6-8%, reaching approximately $540 million by 2027.
• Factors influencing profitability: Competition from newer formulations, potential expansion into additional indications, patent cliffs, and pricing strategies.

Pricing Dynamics

• Per-unit cost: Ranges between $10 and $15.
• Treatment course cost: Typically $2,000 to $4,000 depending on indication and dosage.

Key Market Challenges

• Pricing pressure: As generics enter the market, prices decline.
• Regulatory restrictions: Increasing scrutiny over off-label use.
• Efficacy competition: Newer botulinum toxin formulations with enhanced properties emerging.
• Manufacturing complexity: The complexity of producing botulinum toxins limits rapid scale-up.

Strategic Outlook

Opportunities

• Indication expansion: Neurological and non-neurological uses.
• Biologics partnerships: Collaborations for R&D in neuromodulation.
• Market penetration in emerging regions: Asia-Pacific shows higher growth potential.

Threats

• Patent expiries: Generic and biosimilar entry.
• Alternative therapies: Non-botulinum neuromuscular treatments gaining popularity.
• Regulatory hurdles: Future restrictions can impact the pipeline and sales.

Conclusion

RimabotulinumtoxinB remains a niche but essential biologic in movement disorder therapeutics. Its market size is modest compared to type A toxins but benefits from a steady growth trajectory driven by clinical demand and expanding indications. Competitive pressures and patent expiries pose challenges, but ongoing research and regional expansion can sustain revenue growth.

Key Takeaways

• The global botulinum toxin market grows annually at 7%, with RimabotulinumtoxinB holding an 8% share.
• Revenue has increased from $150 million in 2015 to approximately $370 million in 2022.
• The product’s future hinges on indication expansion, market penetration, and regulatory landscape.
• Patent expiries and biosimilar development pose risks but also create opportunities in emerging markets.
• Expected revenue trajectory projects reaching over $540 million by 2027.

FAQs

1. What are the primary indications for RimabotulinumtoxinB?
   Cervical dystonia and sialorrhea are the main approved indications.

2. How does RimabotulinumtoxinB differ from botulinum toxin A formulations?
   It has a different molecular composition, longer onset time, and is used particularly when toxin A treatments are less effective or contraindicated.

3. What is the main driver of growth in the RimabotulinumtoxinB market?
   The expansion into new indications like hyperhidrosis and increased awareness of movement disorders.

4. What are the main challenges facing RimabotulinumtoxinB’s market expansion?
   Patent expiries, pricing pressures, competition from newer toxins, and regulatory restrictions.

5. Which regions are most promising for growth?
   Asia-Pacific and emerging markets demonstrate high potential due to increasing disease awareness and healthcare infrastructure development.

---

Citations

[1] MarketWatch. (2022). Botulinum toxin market size. Retrieved from https://www.marketwatch.com/

[2] Grand View Research. (2022). Botulinum toxin market analysis. https://www.grandviewresearch.com/

[3] U.S. Food and Drug Administration. (2023). RimabotulinumtoxinB approval details. https://www.fda.gov/